Background Gefitinib is frequently used to treat patients with non-small cell lung cancer
(NSCLC) and is excreted out from cells via the ATP-binding cassette transporter ABCG2 …

Aims: The current study investigates whether or not functional polymorphisms in the ATP-
binding cassette transporter gene ABCG2 might affect gefitinib activity and/or toxicity in non …

Purpose ABCG2 is a half-size ATP-binding cassette transporter implicated in cellular
gefitinib transport. Reportedly, the c. 421C> A ABCG2 gene polymorphism was associated …

Objective The primary purpose of this study was to investigate the correlation between
single nucleotide polymorphisms (SNPs) of ATP binding cassette superfamily G member 2 …

ATP-binding castle protein G2 (ABCG2) is thought to inhibit the activities of certain gefitinib
transporters, thereby affecting drug pharmacokinetics. The C421A polymorphism affects the …

Skin rash, diarrhea and hepatotoxicity are the most common toxicities of Gefitinib, an
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. The present study …

Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase with
activity in non–small-cell lung cancer. Diarrhea and skin toxicity are prominent gefitinib …

The purpose of this study is to investigate associations between allelic variations of ABCG2
and ABCB1 with skin toxicity, diarrhea, liver injury and interstitial lung disease (ILD) in …

Objectives: The ATP-binding cassette (ABC) ABCG2, involved in multidrug resistance (MDR)
in cancer cells, plays an integral role in drug resistance. Single nucleotide polymorphisms …

Background The current study is aimed to examine the impact of pharmacokinetics and
gene polymorphisms of enzymes involving in absorption, distribution, metabolism and …